PriceTargets.com logo

NASDAQ:PLSE - Pulse Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $38.00
  • Forecasted Upside: 72.65 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$22.01 As of 10/20/2021 05:00 PM ET
▲ +0.56 (2.61%)

This chart shows the closing price for PLSE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pulse Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PLSE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PLSE

Analyst Price Target is $38.00
▲ +72.65% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Pulse Biosciences in the last 3 months. The average price target is $38.00, with a high forecast of $46.00 and a low forecast of $28.00. The average price target represents a 72.65% upside from the last price of $22.01.

This chart shows the closing price for PLSE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Pulse Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/10/2021HC WainwrightReiterated RatingBuy$46.00High
7/26/2021StephensInitiated CoverageOverweight$28.00High
3/11/2021Maxim GroupInitiated CoverageBuy$40.00High
2/4/2021HC WainwrightBoost Price TargetBuy$40.00 ➝ $46.00High
1/26/2021HC WainwrightBoost Price TargetBuy$16.00 ➝ $40.00Medium
5/12/2020HC WainwrightUpgradeNeutral ➝ Buy$6.00 ➝ $16.00High
3/17/2020HC WainwrightReiterated RatingHold$6.00High
2/14/2020HC WainwrightDowngradeBuy ➝ Neutral$26.00 ➝ $6.00High
5/1/2019HC WainwrightReiterated RatingBuyLow
2/25/2019HC WainwrightInitiated CoverageBuy ➝ Buy$27.00High
(Data available from 10/20/2016 forward)

News Sentiment Rating

0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/22/2021
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/22/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2021

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Pulse Biosciences logo
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.
Read More

Today's Range

Now: $22.01
Low: $21.01
High: $22.18

50 Day Range

MA: $22.40
Low: $19.99
High: $26.63

52 Week Range

Now: $22.01
Low: $11.60
High: $45.82

Volume

15,711 shs

Average Volume

103,392 shs

Market Capitalization

$651.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63

Frequently Asked Questions

What sell-side analysts currently cover shares of Pulse Biosciences?

The following equities research analysts have issued reports on Pulse Biosciences in the last year: HC Wainwright, Maxim Group, Stephens, and Zacks Investment Research.
View the latest analyst ratings for PLSE.

What is the current price target for Pulse Biosciences?

3 Wall Street analysts have set twelve-month price targets for Pulse Biosciences in the last year. Their average twelve-month price target is $38.00, suggesting a possible upside of 77.2%. HC Wainwright has the highest price target set, predicting PLSE will reach $46.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $28.00 for Pulse Biosciences in the next year.
View the latest price targets for PLSE.

What is the current consensus analyst rating for Pulse Biosciences?

Pulse Biosciences currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PLSE will outperform the market and that investors should add to their positions of Pulse Biosciences.
View the latest ratings for PLSE.

What other companies compete with Pulse Biosciences?

Other companies that are similar to Pulse Biosciences include Glaukos, iRhythm Technologies, Silk Road Medical, Inovio Pharmaceuticals, Pulmonx, Cardiovascular Systems, Treace Medical Concepts, Atrion, OrthoPediatrics, Alphatec, LeMaitre Vascular, Cerus, Sight Sciences, AngioDynamics and Intersect ENT.

How do I contact Pulse Biosciences' investor relations team?

Pulse Biosciences' physical mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The company's listed phone number is (510) 906-4600 and its investor relations email address is [email protected] The official website for Pulse Biosciences is www.pulsebiosciences.com.